Increased LRIG2 expression correlates with a poorer prognosis in patients with oligodendroglioma (Holmlund et al., 2009), cervical SCC (Hedman et al., 2010), non‐small cell lung cancer (Wang et al., 2014), and glioblastoma (Wang et al., 2009). Here, LRIG2 is linked to glioblastoma.